-
Pediatric Clinics of North America Feb 1968
Review
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Erythromycin; Gastrointestinal Diseases; Humans; Oleandomycin; Respiratory Tract Infections; Troleandomycin
PubMed: 4867776
DOI: 10.1016/s0031-3955(16)32093-4 -
Journal of the American Medical... Oct 1958
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Oleandomycin
PubMed: 13587186
DOI: No ID Found -
Pediatric Clinics of North America Nov 1961
Topics: Humans; Oleandomycin; Troleandomycin
PubMed: 13893869
DOI: 10.1016/s0031-3955(16)31199-3 -
Vie Medicale (Paris, France : 1920) Apr 1958
Topics: Anti-Bacterial Agents; Humans; Oleandomycin
PubMed: 13557665
DOI: No ID Found -
Alergia Nov 1964
Topics: Drug Hypersensitivity; Oleandomycin; Toxicology
PubMed: 14277190
DOI: No ID Found -
Tidsskrift For Den Norske Laegeforening... Aug 1957
Topics: Anti-Bacterial Agents; Dermatologic Agents; Oleandomycin
PubMed: 13467905
DOI: No ID Found -
Bulletin of the World Health... 1965At the request of the WHO Expert Committee on Biological Standardization a batch of oleandomycin was submitted to an international collaborative study in six...
At the request of the WHO Expert Committee on Biological Standardization a batch of oleandomycin was submitted to an international collaborative study in six laboratories situated in four countries. In this study the material was assayed by plate diffusion methods, which varied in details of technique and design, against the US Food and Drug Administration's reference preparation for oleandomycin. On the basis of the results obtained the material has been established as the International Standard for Oleandomycin and the International Unit of Oleandomycin is defined as the activity in 0.001176 mg of the International Standard. The US Food and Drug Administration's standard and the International Standard are each part of the same parent batch of oleandomycin and the validity of such an assay has been compared with the more usual assay situation when there is some degree of difference between the preparations under comparison.
Topics: Biological Assay; In Vitro Techniques; International Cooperation; Oleandomycin; World Health Organization
PubMed: 5294593
DOI: No ID Found -
Journal of General Microbiology Jul 1987Resistance to oleandomycin in Streptomyces antibioticus, the producer organism, was studied. The organism was highly resistant in vivo to the antibiotic but sensitive to...
Resistance to oleandomycin in Streptomyces antibioticus, the producer organism, was studied. The organism was highly resistant in vivo to the antibiotic but sensitive to other macrolides and lincosamides. Protein synthesis in vivo by mycelium of S. antibioticus was more resistant to oleandomycin than that by mycelium of Streptomyces albus G, an oleandomycin-sensitive strain, and this resistance was dependent on the age of the culture, older mycelium of S. antibioticus being more resistant to oleandomycin than young mycelium. [3H]Oleandomycin was capable of binding to the same extent to the 50S subunits of the ribosomes of both organisms. Oleandomycin also inhibited in vitro protein synthesis by ribosomes obtained from an oleandomycin-production medium at the time when maximum levels of oleandomycin were being produced. A clear difference between the ability of the two organisms to incorporate exogenous oleandomycin was observed. Thus, while S. albus G took up oleandomycin, S. antibioticus showed a decreased permeability to the antibiotic, suggesting a role for cell permeability in self-resistance.
Topics: Bacterial Proteins; Drug Resistance, Microbial; Oleandomycin; Ribosomes; Streptomyces; Streptomyces antibioticus
PubMed: 3312488
DOI: 10.1099/00221287-133-7-1931 -
The Journal of Antibiotics Mar 2005During the study on the oleandomycin production, we purified a new oleandomycin derivative having a macrolactone of which biosynthesis does not follow the genetic...
During the study on the oleandomycin production, we purified a new oleandomycin derivative having a macrolactone of which biosynthesis does not follow the genetic architecture of the oleandomycin PKS. The molecular formula for the compound was suggested as C35H59NO11 on the basis of the analysis of NMR and HRMS data (m/z 670.4185, Delta-1.9mmu, calcd for C35H60NO11). 13C NMR assignments and analysis of COSY, HMBC and HMQC data suggested that the compound differs from oleandomycin by formation of the olefinic functionality resulting from the dehydration of a hydroxy group in oleandomycin. The new oleandomycin derivative has antibacterial activities similar to those of oleandomycin agaisnt Enterococcus faecalis, Bacillus subtilis and Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Enterococcus faecalis; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Oleandomycin; Staphylococcus aureus; Streptomyces antibioticus
PubMed: 15895528
DOI: 10.1038/ja.2005.23 -
Veterinary Research Communications Jan 2002The pharmacokinetics of oleandomycin (OLD) after intravenous and oral administration, both alone and after intramuscular pretreatment with metamizole or dexamethasone,... (Comparative Study)
Comparative Study
The pharmacokinetics of oleandomycin (OLD) after intravenous and oral administration, both alone and after intramuscular pretreatment with metamizole or dexamethasone, were studied in healthy dogs. After intravenous injection of OLD alone (10 mg/kg as bolus), the elimination half-life (t 1/2 beta, volume of distribution (Vd,area), body clearance (ClB) and area under the concentration time curve (AUC) were 1.60 h, 1.11 L/kg. 7.36 (ml/kg)/min and 21.66 microg h/ml, respectively. There were no statistically significant differences following pretreatment with metamizole or dexamethasone. After oral administration of OLD alone, the t 1/2 beta, maximum plasma concentrations (Cmax), time of Cmax (tmax), mean absorption time (MAT) and absolute bioavailability (Fabs) were 1.6 h, 5.34 microg/ml, 1.5 h, 1.34 h and 84.29%, respectively. Pretreatment with metamizole caused a significantly decreased value for Cmax (2.93 microg/ml) but the MAT value (2.23 h) was significantly increased. Statistically significant changes in the pharmacokinetic parameters of OLD following oral administration were also observed as a result of pretreatment with dexamethasone. The Cmax was increased (8.24 microg/ml) and the tmax (0.5 h) and MAT (0.45 h) were lower.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Cross-Over Studies; Dexamethasone; Dipyrone; Dogs; Drug Interactions; Female; Injections, Intravenous; Oleandomycin
PubMed: 11860088
DOI: 10.1023/a:1013309922721